AstraZeneca vaccine being tweaked to fight S. Africa variant
The lead researcher of the Oxford-AstraZeneca vaccine says she expects to have a modified jab to cope with the South Africa coronavirus variant by the autumn
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Developers of the Oxford-AstraZeneca vaccine expect to have a modified jab to cope with the South Africa coronavirus variant by autumn, the vaccine’s lead researcher said Sunday.
Health officials in Britain are trying to contain the spread of the variant first identified in South Africa amid concerns that it is more contagious or resistant to existing vaccines. More than 100 cases of the South African variant have been found in the U.K.
Sarah Gilbert lead researcher for the Oxford team told the BBC on Sunday that “we have a version with the South African spike sequence in the works.”
“It looks very likely that we can have a new version ready to use in the autumn,” she added.
Her comments came as Oxford University said that early data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection” against mild disease caused by the South Africa variant.
The study, which has not yet been peer reviewed, involved 2,000 people, most of whom were young and healthy. The volunteers’ average age was 31.
“Protection against moderate-severe disease, hospitalization or death could not be assessed in this study as the target population were at such low risk,” Oxford University said.
Robin Shattock, a scientist who is leading the coronavirus vaccine research at Imperial College London, urged caution about the study’s early findings. But he said it was “concerning to some extent that we’re seeing that it’s not effective against mild or moderate disease.”
Authorities in England last week went house-to-house to administer COVID-19 testing in eight areas where the South Africa variant is believed to be spreading, after a handful of cases were found in people who had no contact with the country or anyone who travelled there.
The testing blitz is a bid to snuff out the variant before it spreads widely and undermines the U.K.’s vaccination rollout. Public health officials are concerned about the South Africa variant because it contains a mutation of the virus’ characteristic spike protein, which is targeted by existing vaccines.
Britain has seen Europe's deadliest coronavirus outbreak, with over 112,000 confirmed deaths, but it has embarked on a speedier vaccination plan than the neighboring European Union. So far the U.K. has given a first coronavirus vaccine jab to about 11.5 million people.
___
Follow AP coverage of the coronavirus pandemic at:
https://apnews.com/hub/coronavirus-pandemic
https://apnews.com/hub/coronavirus-vaccine
https://apnews.com/UnderstandingtheOutbreak
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.